Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Related Issues

  • 1
    News

    Survey: Hydroxychloroquine use fairly common in COVID-19

    April 29, 2020

    Testing and preparedness have increased, but a return to normal life could take another 6 months.

  • 1
    News

    FDA reiterates hydroxychloroquine limitations for COVID-19

    April 24, 2020

    An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial.

  • News

    Angiotensin drugs and COVID-19: More reassuring data

    April 24, 2020

    Data from one Wuhan hospital show no difference in COVID-19 severity or mortality in patients with hypertension taking ACE inhibitors or ARBs. Other reassuring studies are also emerging.

  • 1
    News

    Hydroxychloroquine ineffective for COVID-19, VA study suggests

    April 23, 2020

    The retrospective study, which included data from 368 men hospitalized with confirmed COVID-19 and treated in VA medical centers, showed an association between HCQ and higher mortality.

  • News

    Signature STEMI sign may be less diagnostic in the COVID-19 age

    April 22, 2020

    ST-segment elevation, often a ticket to the cath lab, may not indicate STEMI as reliably as before hospitals started to fill with COVID-19 patients, who may have other ST-segment–elevating conditions.

  • News

    COVID-19: U.S. cardiology groups reaffirm continued use of RAAS-active drugs

    March 18, 2020

    Experts give ACE inhibitors and ARBs, cornerstones of cardiology therapy, a thumbs up despite a hypothetical adverse COVID-19 effect.

  • News

    COVID-19: Older patients with cancer especially vulnerable

    March 12, 2020

    Expert advises diligence in screening cancer patients and commonsense preventative measures.

  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences